Published online Apr 7, 2023. doi: 10.3748/wjg.v29.i13.2034
Peer-review started: December 13, 2022
First decision: January 11, 2023
Revised: January 21, 2023
Accepted: March 20, 2023
Article in press: March 20, 2023
Published online: April 7, 2023
Processing time: 114 Days and 21.2 Hours
Sepsis is a common disease in intensive care units, with high morbidity and mortality. Our previous study confirmed the presence of gut microbiota disorders in patients with sepsis. The combination of disease and gut microbiota disorders lead to the development of multiple organ dysfunction and clinical deterioration of the patient. Nutritional support is an important part of the treatment of critically ill patients. Proper modalities of nutritional support can improve nutrition, immunity, and intestinal microecology. The exploration of early nutritional support in patients with sepsis from the perspective of intestinal microecology is important to optimize nutritional support and improve prognosis.
The recommendations about the choice of nutritional support modalities are largely based on expert consensus, although the level of evidence is low. Nutritional support has a significant impact on intestinal microecology; to date, the modalities of nutritional support in sepsis have not been evaluated from the perspective of intestinal microecology. This perspective can provide new insights into the optimization of the modalities for nutritional support in sepsis.
The main objective was to determine the optimal modality of early nutritional support for patients with sepsis from the perspective of intestinal microecology. We applied different nutritional modalities for early and short-duration nutritional support in patients with sepsis and found differences in intestinal bacterial composition, short-chain fatty acids (SCFAs), and nutritional and immune indicators. Our results revealed for the first time that total enteral nutrition (TEN) is a good modality for early nutritional support in patients with sepsis. This study offers a new perspective for optimizing nutritional support modalities in sepsis.
Thirty patients with sepsis who were admitted to the intensive care unit of the General Hospital of Ningxia Medical University, China, between 2019 and 2021 with indications for nutritional support, were randomly assigned to one of three different modalities of nutritional support. For 5 d, nutritional support was administered to each patient using one of the following modalities: TEN group, total parenteral nutrition (TPN group), and supplemental parenteral nutrition (SPN group). Blood and stool specimens were collected before and after nutritional support was administered, and changes in gut microbiota, SCFAs, and immune and nutritional indicators were detected and compared among the three groups.
Patients were assessed before and after the administration of nutritional support. The following differences were observed in the three groups after nutritional support: (1) Differences in the gut bacteria (Enterococcus increased in the TEN group, Campylobacter decreased in the TPN group, and Dialister decreased in the SPN group); (2) different trends in SCFA concentrations (increase in SCFAs in the TEN group except for caproic acid, improvement of acetic and propionic acid only in the TPN group, and decreasing trend in SCFA production in the SPN group); and (3) significant improvement in the nutritional and immunological indicators in the TEN and SPN groups, with improvement in immunoglobulin G levels only in the TPN group. Furthermore, and significant correlations were found between the gut bacteria, SCFAs, and nutritional and immunological indicators.
Our results indicate that TEN is the optimal modality for early nutritional support in patients with sepsis from the perspective of intestinal microecology.
Future research should focus on how different nutritional support modalities affect the structural and metabolic changes in gut microbiota composition and the underlying mechanisms. Our research group will explore these questions in a large scale clinical trial with a longer intervention time.